Developments in Carbohydrate-Based Metzincin Inhibitors

Area of Science:

• Biochemistry and Medicinal Chemistry
• Enzymology
• Drug Discovery

Background:

• Matrix metalloproteinases (MMPs) and ADAMs are metzincins crucial in pathologies like cancer and inflammation.
• Current metzincin inhibitors face challenges including low selectivity, poor solubility, and toxicity.
• Developing effective inhibitors is critical for treating various diseases.

Purpose of the Study:

• To review the development of carbohydrate-based and azasugar-based derivatives as metzincin inhibitors.
• To evaluate the activity of these novel compounds in pathological models.
• To highlight strategies for improving inhibitor solubility and bioavailability.

Main Methods:

• Synthesis of carbohydrate-based compounds linking hydrophilic sugar moieties to lipophilic scaffolds.
• Evaluation of inhibitor activity against metzincin enzymes.
• Assessment of compound efficacy in preclinical pathological models.

Main Results:

• Carbohydrate-based derivatives offer improved solubility and bioavailability compared to traditional inhibitors.
• Sugar- and azasugar-based compounds demonstrate promising inhibitory activity against metzincins.
• These novel inhibitors show potential in various disease models.

Conclusions:

• Carbohydrate-based strategies represent a viable approach to overcome limitations in metzincin inhibitor development.
• Sugar- and azasugar-based derivatives are promising candidates for future therapeutic applications.
• Further research into these compounds could lead to improved treatments for metzincin-related diseases.